100
Participants
Start Date
December 28, 2017
Primary Completion Date
December 20, 2027
Study Completion Date
December 21, 2027
dabrafenib
dabrafenib is available in capsules (50mg and 75mg) taken twice a day
trametinib
trametinib is available in tablets (0.5mg, 2mg dose)
COMPLETED
Novartis Investigative Site, Debrecen
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Innsbruck
COMPLETED
Novartis Investigative Site, Berlin
COMPLETED
Novartis Investigative Site, Hamburg
RECRUITING
National Institute Of Health, Bethesda
RECRUITING
Novartis Investigative Site, Madrid
COMPLETED
Novartis Investigative Site, Madrid
RECRUITING
Novartis Investigative Site, Madrid
COMPLETED
James Cancer Hospital and Solove Research Institute Ohio State, Columbus
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Nantes
COMPLETED
Novartis Investigative Site, Mannheim
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Heidelberg
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Lyon
COMPLETED
Mary Crowley Cancer Research, Dallas
COMPLETED
Novartis Investigative Site, Paris
RECRUITING
Honor Health Research Institute, Scottsdale
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Songkhla
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Villejuif
COMPLETED
Novartis Investigative Site, Beijing
COMPLETED
Novartis Investigative Site, Buenos Aires
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Copenhagen
COMPLETED
Novartis Investigative Site, Budapest
COMPLETED
Novartis Investigative Site, Kashiwa
COMPLETED
Novartis Investigative Site, Chuo Ku
COMPLETED
Novartis Investigative Site, Rotterdam
ACTIVE_NOT_RECRUITING
Novartis Investigative Site, Utrecht
RECRUITING
Novartis Investigative Site, Barcelona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY